Cargando…

Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai

OBJECTIVE: To summarize the use rate, safety, efficacy of antithrombotics in stroke/transient ischemic attack (TIA) prevention, and reasons for not using dabigatran etexilate (DE) in Shanghai, China. METHODS: Non-valvular atrial fibrillation (NVAF)-associated stroke patients were prospectively regis...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Feng-Di, Zhao, Rong, Wang, Xue-Mei, Wang, Shuo, Shen, Xiao-Lei, Tao, Xiao-Xiao, Zheng, Bo, Peng, Jia-Li, Zhang, Hui, Mo, Ran, Tong, Yan, Li, Wen-Ting, Feng, Xiao-Yan, Li, Ge-Fei, Shu, Liang, Liu, Jian-Ren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: KeAi Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643732/
https://www.ncbi.nlm.nih.gov/pubmed/29063008
http://dx.doi.org/10.1016/j.cdtm.2015.11.005
_version_ 1783271597435518976
author Liu, Feng-Di
Zhao, Rong
Wang, Xue-Mei
Wang, Shuo
Shen, Xiao-Lei
Tao, Xiao-Xiao
Zheng, Bo
Peng, Jia-Li
Zhang, Hui
Mo, Ran
Tong, Yan
Li, Wen-Ting
Feng, Xiao-Yan
Li, Ge-Fei
Shu, Liang
Liu, Jian-Ren
author_facet Liu, Feng-Di
Zhao, Rong
Wang, Xue-Mei
Wang, Shuo
Shen, Xiao-Lei
Tao, Xiao-Xiao
Zheng, Bo
Peng, Jia-Li
Zhang, Hui
Mo, Ran
Tong, Yan
Li, Wen-Ting
Feng, Xiao-Yan
Li, Ge-Fei
Shu, Liang
Liu, Jian-Ren
author_sort Liu, Feng-Di
collection PubMed
description OBJECTIVE: To summarize the use rate, safety, efficacy of antithrombotics in stroke/transient ischemic attack (TIA) prevention, and reasons for not using dabigatran etexilate (DE) in Shanghai, China. METHODS: Non-valvular atrial fibrillation (NVAF)-associated stroke patients were prospectively registered as an electronic database. Use rate of antithrombotics and reasons for not using DE were extracted during follow-up. Patients' baseline characteristics, recurrent ischemic stroke/TIA events and bleeding complications were analyzed. PATIENTS: From April 2012 to August 2014, 110 inpatients with NVAF-associated stroke were studied in our hospital. NVAF was diagnosed by 12-lead electrocardiogram, 24 h Holter and echocardiography. RESULTS: Before introduction of DE (April 2013), use rates of warfarin and antiplatelets were 28.9% (11/38) and 60.5% (23/38) respectively; after that, use rates of warfarin, DE, and antiplatelets were 20.8% (15/72), 12.5% (9/72), and 43.1% (31/72). The DE did not improve use of anticoagulants (P = 0.639). There were 19 (17.3%) recurrent ischemic stroke events up to October 2015; two (9.5%) in the non-user group, 10 (18.5%) in the antiplatelet group, and seven (20.0%) in the anticoagulants group (P = 0.570). Furthermore, recurrence rates were similar between the DE group (20.0%) and the Warfarin group (20.0%, P = 1.000). The most common reason for not using DE was financial concerns (61.0%), followed by inconvenience to purchase (14.0%) and hemorrhage concerns (11.0%). Two patients using warfarin found fecal occult blood so they stopped warfarin and began to use antiplatelet drugs. No bleeding event occurred in the other groups. Only one patient had side effects (dyspepsia and gastroesophageal reflux) from DE. CONCLUSION: The use rate of either DE or warfarin in Shanghai was low; DE had not improved anticoagulation therapy for NVAF patients in Shanghai mainly because DE had not been covered by health insurance.
format Online
Article
Text
id pubmed-5643732
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher KeAi Publishing
record_format MEDLINE/PubMed
spelling pubmed-56437322017-10-23 Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai Liu, Feng-Di Zhao, Rong Wang, Xue-Mei Wang, Shuo Shen, Xiao-Lei Tao, Xiao-Xiao Zheng, Bo Peng, Jia-Li Zhang, Hui Mo, Ran Tong, Yan Li, Wen-Ting Feng, Xiao-Yan Li, Ge-Fei Shu, Liang Liu, Jian-Ren Chronic Dis Transl Med Original Article OBJECTIVE: To summarize the use rate, safety, efficacy of antithrombotics in stroke/transient ischemic attack (TIA) prevention, and reasons for not using dabigatran etexilate (DE) in Shanghai, China. METHODS: Non-valvular atrial fibrillation (NVAF)-associated stroke patients were prospectively registered as an electronic database. Use rate of antithrombotics and reasons for not using DE were extracted during follow-up. Patients' baseline characteristics, recurrent ischemic stroke/TIA events and bleeding complications were analyzed. PATIENTS: From April 2012 to August 2014, 110 inpatients with NVAF-associated stroke were studied in our hospital. NVAF was diagnosed by 12-lead electrocardiogram, 24 h Holter and echocardiography. RESULTS: Before introduction of DE (April 2013), use rates of warfarin and antiplatelets were 28.9% (11/38) and 60.5% (23/38) respectively; after that, use rates of warfarin, DE, and antiplatelets were 20.8% (15/72), 12.5% (9/72), and 43.1% (31/72). The DE did not improve use of anticoagulants (P = 0.639). There were 19 (17.3%) recurrent ischemic stroke events up to October 2015; two (9.5%) in the non-user group, 10 (18.5%) in the antiplatelet group, and seven (20.0%) in the anticoagulants group (P = 0.570). Furthermore, recurrence rates were similar between the DE group (20.0%) and the Warfarin group (20.0%, P = 1.000). The most common reason for not using DE was financial concerns (61.0%), followed by inconvenience to purchase (14.0%) and hemorrhage concerns (11.0%). Two patients using warfarin found fecal occult blood so they stopped warfarin and began to use antiplatelet drugs. No bleeding event occurred in the other groups. Only one patient had side effects (dyspepsia and gastroesophageal reflux) from DE. CONCLUSION: The use rate of either DE or warfarin in Shanghai was low; DE had not improved anticoagulation therapy for NVAF patients in Shanghai mainly because DE had not been covered by health insurance. KeAi Publishing 2016-01-08 /pmc/articles/PMC5643732/ /pubmed/29063008 http://dx.doi.org/10.1016/j.cdtm.2015.11.005 Text en © 2016 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Liu, Feng-Di
Zhao, Rong
Wang, Xue-Mei
Wang, Shuo
Shen, Xiao-Lei
Tao, Xiao-Xiao
Zheng, Bo
Peng, Jia-Li
Zhang, Hui
Mo, Ran
Tong, Yan
Li, Wen-Ting
Feng, Xiao-Yan
Li, Ge-Fei
Shu, Liang
Liu, Jian-Ren
Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai
title Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai
title_full Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai
title_fullStr Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai
title_full_unstemmed Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai
title_short Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai
title_sort does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: an inpatient registration study in shanghai
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643732/
https://www.ncbi.nlm.nih.gov/pubmed/29063008
http://dx.doi.org/10.1016/j.cdtm.2015.11.005
work_keys_str_mv AT liufengdi doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai
AT zhaorong doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai
AT wangxuemei doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai
AT wangshuo doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai
AT shenxiaolei doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai
AT taoxiaoxiao doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai
AT zhengbo doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai
AT pengjiali doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai
AT zhanghui doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai
AT moran doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai
AT tongyan doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai
AT liwenting doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai
AT fengxiaoyan doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai
AT ligefei doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai
AT shuliang doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai
AT liujianren doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai